VEA
ACOR

Virtus ETF Advisers’s Acorda Therapeutics ACOR Stock Holding History

Virtus ETF Advisers’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-404
Closed -$644K – 449
2019
Q1 		$644K Buy
404
+95
+31% +$171K 1.37% 23
2018
Q4 		$578K Buy
309
+102
+49% +$222K 0.1% 53
2018
Q3 		$488K Buy
207
+14
+7% +$43.3K 0.05% 129
2018
Q2 		$665K Sell
193
-171
-47% -$524K 0.59% 117
2018
Q1 		$1.03M Sell
364
-21
-5% -$62.9K 0.9% 38
2017
Q4 		$991K Sell
385
-115
-23% -$327K 1.24% 20
2017
Q3 		$1.42M Hold
500
– – 0.19% 37
2017
Q2 		$1.18M Buy
500
+83
+20% +$164K 0.18% 38
2017
Q1 		$1.05M Buy
417
+40
+11% +$115K 0.19% 63
2016
Q4 		$850K Buy
377
+176
+88% +$418K 0.25% 79
2016
Q3 		$505K Buy
201
+25
+14% +$74.6K 0.24% 73
2016
Q2 		$539K Buy
176
+48
+38% +$156K 0.4% 44
2016
Q1 		$408K Buy
+128
New +$531K 0.56% 49

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Virtus ETF Advisers's ACOR Position: Q2 2019 in Review

Virtus ETF Advisers sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 404 shares — an estimated $644K sold.

Virtus ETF Advisers first reported a position in ACOR in Q1 2016 and held it in 13 quarters. The position peaked at $1.42M in Q3 2017. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

  • Virtus ETF Advisers reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Virtus ETF Advisers sold 404 Acorda Therapeutics shares in Q2 2019, an estimated $644K.
  • Virtus ETF Advisers first reported a position in Acorda Therapeutics in Q1 2016 and held it in 13 quarters.
  • Virtus ETF Advisers's Acorda Therapeutics position peaked at $1.42M in Q3 2017.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.